Advances in BABE

In pharmacology, bioavailability (BA) is a subcategory of ingestion and is the part of a managed measurement of unaltered medication that achieves the systemic flow, one of the important pharmacokinetic properties of medications. Bioavailability is one of the crucial apparatuses in pharmacokinetics, as bioavailability must be considered when computing doses for non-intravenous courses of organization.

  • Application of Nano technology to improve bioavailabilty
  • Innovative strategies
  • Isotope drug studies in man
  • Bioequivalence Criteria
  • Risks in bioequivalence assessment
  • Requirement to determine the active principle
  • SUPAC: scale-up and for post-approval changes
  • Relevance of bioequivalence in approving generic copies of drug products
  • Electronic regulatory submission and review
  • Drug application regulatory compliance
  • New drug quality assessment
  • Highly variable and low permeable drugs
  • Complex generics

Related Conference of Advances in BABE

August 20-21, 2018

12th Asian Biologics and Biosimilars Congress

Tokyo, Japan
August 29-30, 2018 |

International Conference and Exhibition on Drug Safety & Pharmacovigilance

Park Inn By Radisson Toronto Airport West, 175 Derry Road East, Mississauga, ON, L5T 2Z7, Canada
September 18-19, 2018

6 th European Biopharma Congress

Amsterdam, Netherlands
October 18-20, 2018

18th World Pharma Congress

Warsaw, Poland
November 14-15 | 2018

13th International Conference on Biosimilars and Biologics

Lisbon | Portugal

Advances in BABE Conference Speakers

Recommended Sessions

Related Journals

Are you interested in